MONIQUE JACKSON: Open Payments
NPI 1952338543 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,019 in 49 payments from 25 companies in 2025. Trend: 2023 $2,322 · 2024 $4,511 · 2025 $6,019
Food & beverage: $6,019
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 9 | $1,196 |
| Janssen Pharmaceuticals, Inc | 7 | $690 |
| Janssen Biotech, Inc. | 5 | $661 |
| ViiV Healthcare Company | 3 | $365 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $363 |
| Alexion Pharmaceuticals, Inc. | 2 | $253 |
| CSL Behring | 2 | $225 |
| Neurocrine BioSciences, Inc. | 1 | $167 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $145 |
| Madrigal Pharmaceuticals | 1 | $135 |
Products named: INVEGA SUSTENNA, RYBREVANT, Yeztugo, CAPLYTA, Hizentra, INGREZZA, Kerendia, REZDIFFRA.
Industry payments across CA — which companies pay providers there.
